Incyte (INCY) Q4 2024 earnings summary

Executive summary

• Total revenues for 2024 grew 15% year-over-year to $4.2 billion, driven by strong performances from Jakafi and Opzelura, with steady growth since 2020.

• Jakafi net sales reached $2.8 billion (+8% Y/Y), and Opzelura net sales surged to $508 million (+50% Y/Y), with growth across all indications and geographies.

• Four new product launches, including Niktimvo for chronic GVHD, are expected in 2025, with significant near-term revenue potential.

• Robust pipeline with multiple pivotal data readouts, at least three Phase 3 study initiations, and seven proof-of-concept readouts anticipated in 2025.

• Operating margins expanded, and the company ended 2024 with $2.2 billion in cash and no debt.

Financial highlights

• Q4 2024 total revenues were $1.2 billion, up 16% year-over-year; full-year net product revenues were $3.619 billion (+14% Y/Y).

• Q4 Jakafi revenue grew 11% Y/Y to $773 million; full-year Jakafi revenue up 8% to $2.8 billion.

• Q4 Opzelura revenue was $162 million, up 48% Y/Y; full-year Opzelura revenue was $508 million, up 50%.

• Royalty revenues for 2024 totaled $579 million (+11% Y/Y).

• Ended 2024 with $2.2 billion in cash and no debt; completed $2 billion share repurchase and $783 million Escient acquisition.

Outlook and guidance

• 2025 Jakafi net product revenue expected between $2.925 billion and $2.98 billion, driven by PV demand.

• 2025 Opzelura net product revenue expected between $630 million and $670 million, with growth in AD, vitiligo, and pediatric AD launch.

• Other oncology products expected to generate $415 million-$455 million in 2025.

• R&D expenses projected at $1.93 billion-$1.96 billion; SG&A at $1.28 billion-$1.31 billion; COGS at 8.5%-9% of net product revenues.

• Four new product launches and multiple pivotal trial readouts anticipated in 2025.